Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Revenue (2020 - 2025)

Historic Revenue for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $53.8 million.

  • Tango Therapeutics' Revenue rose 36360.82% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.5 million, marking a year-over-year increase of 5328.46%. This contributed to the annual value of $42.1 million for FY2024, which is 1517.23% up from last year.
  • As of Q3 2025, Tango Therapeutics' Revenue stood at $53.8 million, which was up 36360.82% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Revenue registered a high of $53.8 million during Q3 2025, and its lowest value of $3.2 million during Q2 2025.
  • For the 5-year period, Tango Therapeutics' Revenue averaged around $10.7 million, with its median value being $6.4 million (2022).
  • The largest annual percentage gain for Tango Therapeutics' Revenue in the last 5 years was 36360.82% (2025), contrasted with its biggest fall of 8399.5% (2025).
  • Over the past 5 years, Tango Therapeutics' Revenue (Quarter) stood at $5.7 million in 2021, then rose by 12.16% to $6.4 million in 2022, then fell by 15.29% to $5.4 million in 2023, then dropped by 24.19% to $4.1 million in 2024, then surged by 1207.04% to $53.8 million in 2025.
  • Its Revenue stands at $53.8 million for Q3 2025, versus $3.2 million for Q2 2025 and $5.4 million for Q1 2025.